<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since continuous infusion of <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> and of <z:chebi fb="2" ids="31355">carboplatin</z:chebi> have shown efficacy and reduced toxicity in early phase studies in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 34 elderly patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were treated with continuous infusion <z:chebi fb="0" ids="41977">daunorubicin</z:chebi>, 30 mg/m2 per day, from day 1 to day 4, and <z:chebi fb="2" ids="31355">carboplatin</z:chebi>, 200 mg/m2 per day from day 3 to day 7 </plain></SENT>
<SENT sid="1" pm="."><plain>Seven patients had therapy-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and/or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> following a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> at diagnosis, 15 were in first and two in second relapse, and 10 were resistant to previous <z:chebi fb="0" ids="48120">anthracycline</z:chebi> and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Nine patients or 26%, with a 95% confidence interval (CI) ranging from 18-67%, achieved complete remission, including one patient at diagnosis (14%, CI: 0-58%), seven with relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (41%, CI: 18-67%), and one with resistant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (10%, CI: 0-45%) </plain></SENT>
<SENT sid="3" pm="."><plain>Median durations of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> below 0.5 x 10(9)/l and of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> below 20 x 10(9)/l were 24 and 20 days respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Severe toxicity included <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in 20 patients (59%), <z:mp ids='MP_0001914'>bleeding</z:mp> in two (6%), <z:hpo ids='HP_0001627'>cardiac anomalies</z:hpo> in two (6%), and <z:hpo ids='HP_0002013'>vomiting</z:hpo> in one (3%) </plain></SENT>
<SENT sid="5" pm="."><plain>Overall four patients (12%) died from chemotherapy related toxicity and 21 (62%) had resistant disease </plain></SENT>
<SENT sid="6" pm="."><plain>Median overall survival was 4 months and median disease-free survival 8 months </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that this regimen had efficacy with reduced toxicity in relapsed patients </plain></SENT>
<SENT sid="8" pm="."><plain>Higher dosages for the same drugs could be tolerated by better risk patients for precise evaluation of cross reactivity with <z:chebi fb="0" ids="28680">cytarabine</z:chebi>-based regimens </plain></SENT>
</text></document>